Literature DB >> 12182159

Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury.

M Kawashima1, J yatsunami, Y Fukuno, M Nagata, M Tominaga, S Hayashi.   

Abstract

14-membered ring macrolides have been reported to have anti-inflammatory effects and to decrease neutrophil infiltration into the airways in chronic lower respiratory tract diseases. This study investigated the potential inhibitory effects of macrolide antibiotics on bleomycin-induced acute lung injury. Four drugs were studied: two 14-membered ring macrolides, clarithromycin (CAM) and roxithromycin (RXM); a 15-membered ring macrolide, azithromycin (AZM); and a 16-membered ring macrolide, josamycin (JM). Their effects were compared with macrolide untreated, pretreated, and post-treated groups. An acute lung injury was inhibited by pretreatment with CAM or RXM, which significantly ameliorated the bleomycin-induced increases in the total cell and neutrophil counts in bronchoalveolar lavage (BAL) fluids and the wet lung weight. The pretreatment with CAM or RXM also suppressed inflammatory cell infiltration and interstitial lung edema in the histopathological study. These inhibitory effects were associated with a decreased KC concentration in the BAL fluid and a decreased number of apoptotic cells in the lungs. Posttreatment with CAM or RXM had no marked inhibitory effects. Pretreatment with AZM was much less effective, and JM showed no inhibitory effects. These findings suggest that 14-membered ring macrolides have different effects on inflammatory lung disease than 15- and 16-membered ring macrolides and may be therapeutic agents for acute lung injury and pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182159     DOI: 10.1007/pl00021246

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  14 in total

1.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

Review 2.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

3.  Macrolide antibiotics and survival in patients with acute lung injury.

Authors:  Allan J Walkey; Renda S Wiener
Journal:  Chest       Date:  2011-11-23       Impact factor: 9.410

Review 4.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.

Authors:  Yasuki Yasuda; Kei Kasahara; Fumiko Mizuno; Kazuyuki Nishi; Keiichi Mikasa; Eiji Kita
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

Review 6.  Current Pharmacological Approach to ARDS: The Place of Bosentan.

Authors:  Omer Araz
Journal:  Eurasian J Med       Date:  2020-02

Review 7.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

8.  Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients.

Authors:  Fabienne D Simonis; Gianfranco de Iudicibus; Olaf L Cremer; David S Y Ong; Tom van der Poll; Lieuwe D Bos; Marcus J Schultz
Journal:  Ann Transl Med       Date:  2018-01

9.  The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis.

Authors:  Ajit A Kulkarni; Thomas H Thatcher; Hsi-Min Hsiao; Keith C Olsen; Robert Matthew Kottmann; Jason Morrissette; Terry W Wright; Richard P Phipps; Patricia J Sime
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

10.  Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury.

Authors:  Laura Amado-Rodríguez; Adrián González-López; Inés López-Alonso; Alina Aguirre; Aurora Astudillo; Estefanía Batalla-Solís; Jorge Blazquez-Prieto; Emilio García-Prieto; Guillermo M Albaiceta
Journal:  Respir Res       Date:  2013-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.